 Stock analysts at Maxim Group began coverage on shares of Aridis Pharmaceuticals NASDAQ:ARDS in a research report issued to clients and investors on Friday, TipRanks reports. The brokerage set a buy rating and a 17.00 price target on the stock. Maxim Groups price objective indicates a potential upside of 172.00 from the stocks current price. ... 